BAX and non-small cell lung carcinoma: The NSCLC cells are Bax deficient due to the overexpression of Bax inhibitor-1 protein (163), which could be compensated by the upregulation in Bax expression brought about by the rapamycin treatment, thereby enhancing the ABT-737 mediated apoptosis (164).